Wu Q, Li Q, Qin Y. A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer. Lung Cancer 2025;203:108533.
PMID: 40220717